Newspaper publication of extracts of Consolidated Annual Financial Results for the Quarter and Financial Year ended March 31, 2025.
ROSSARI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Rossari Biotech has published extracts of its consolidated audited financial results for Q4 FY25 and the full year ended March 31, 2025 in Financial Express (English) and Loksatta (Marathi) newspapers, as required under SEBI LODR Regulations. Total income from operations for FY25 stood at about Rs. 20,002.94 million, with Q4 FY25 revenue at about Rs. 5,795.02 million versus Rs. 4,721.15 million in Q4 FY24. Net profit after tax and exceptional items for FY25 was about Rs. 1,363.11 million, while Q4 FY25 net profit was about Rs. 344.44 million compared with Rs. 341.32 million in Q4 FY24. Basic and diluted EPS for the full year came in at Rs. 110.73. The results were reviewed by the Audit Committee and approved by the Board on April 25, 2025.
This is a routine regulatory compliance filing — the company is simply republishing already-approved quarterly and annual results in newspapers, so there is no new fundamental information for shareholders beyond confirming strong full-year revenue growth.